Pineapple juice as a negative oral contrast agent in magnetic resonance cholangiopancreatography: A preliminary evaluation

British Journal of Radiology

Volumn 77, Issue 924, 2004, Pages 991-999

  Riordan, R D ^a   Khonsari, M ^a   Jeffries, J ^a   Maskell, G F ^a   Cook, Philip G ^a  

^a ROYAL CORNWALL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BARIUM; DIATRIZOATE; FERUMOXSIL; MANGANESE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT;

ADULT; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BIOASSAY; COMMON BILE DUCT; CONCENTRATION (PARAMETERS); CONTRAST RADIOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEPATIC DUCT; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; IMAGING SYSTEM; IN VITRO STUDY; INGESTION; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MALE; NORMAL HUMAN; PANCREAS DUCT; PINEAPPLE JUICE; RADIOLOGIST; RELAXATION TIME; SIDE EFFECT; SIGNAL PROCESSING; STANDARD; STATISTICAL SIGNIFICANCE; VATER PAPILLA; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; ANANAS; BEVERAGES; BILIARY TRACT; CHOLANGIOPANCREATOGRAPHY, MAGNETIC RESONANCE; CONTRAST MEDIA; FEMALE; HUMANS; MALE; MANGANESE; MIDDLE AGED; PHANTOMS, IMAGING; PLANT EXTRACTS;

EID: 11244275485     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/36674326     Document Type: Article

References (22)

1. Hirohashi S, Hirohashi R, Uchida H, et al. MR cholangiopancreatography and MR urography: improved enhancement with a negative oral contrast agent. Radiology 1997;203: 281-5.
2. Fulcher AS, Turner MA. Pitfalls of MR cholangiopancreatography (MRCP). J Comput Assist Tomogr 1998;22:845-50.
3. Laubenberger J, Buchert M, Schneider B, Blum U, Hennig J, Langer M. Breath-hold projection magnetic resonance-cholangio-pancreaticography (MRCP): a new method for the examination of the bile and pancreatic ducts. Magn Reson Med 1995;33:18-23.
4. Petersein J, Reisinger W, Mutze S, Hamm B. Value of negative oral contrast media in MR cholangiopancreatography (MRCP). Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 2000;172:55-60.
5. Obenauer S, Fischer U, Heuser M, Wilke R, Grabbe E. The optimization of MR cholangiopancreatography. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1999; 171:450-4.
6. Lecesne R, Drouillard J, Cisse R, Schiratti M. Contribution of Abdoscan in MRI cholangio-pancreatography and MRI urography. J Radiol 1998;79:573-5.
7. Blandino A, Gaeta M, Mazziotti S, Settiner N, Pandolfo I. Use of oral superparamagnetic contrast media in cholangiopancreatography with TSE single-shot magnetic resonance. Radiol Med (Torino) 1998;96:87-91.
8. Papanikolaou N, Karantanas A, Maris T, Gourtsoyiannis N. MR cholangiopancreatography before and after oral blueberry juice administration. J Comput Assist Tomogr 2000;24:229-34.
9. Hiraishi K, Narabayashi I, Fujita O, Yamamoto K, Sagami A, Hisada Y, et al. Blueberry juice: preliminary evaluation as an oral contrast agent in gastrointestinal MR imaging. Radiology 1995;194:119-23.
10. Albrich H, Herfarth H, Schreyer A, Andus T, Schoelmerich J, Feuerbach S, et al. Tasty, cost effective and healthy: Abdominal MRI in patients with IBD with a new oral contrast agent. Gastroenterology 2000;118:A1077.
11. Schreyer AG, Herfarth H, Kikinis R, Seitz J, Schlölmerich J, Geissler A, et al. 3D modeling and virtual endoscopy of the small bowel based on magnetic resonance imaging in patients with inflammatory bowel disease. Invest Radiol 2002;37: 528-33.
12. In den Kleef JJ, Cuppen JJ. RLSQ: T1, T2, and rho calculations, combining ratios and least squares. Magn Reson Med 1987;5:513-24.
13. Freeman ML. Adverse outcomes of endoscopic retrograde cholangiopancreatography. Rev Gastroenterol Disord 2002;2: 147-68.
14. Dinesh L, Lane M, Wong P. Complications of endoscopic retrograde cholangiopancreatography. NZ Med J 2003; 116:U496.
15. Lee MG, Lee HJ, Kim MH, Kang EM, Kim YH, Lee SG, et al. Extrahepatic biliary diseases: 3D MR cholangiopancreatography compared with endoscopic retrograde cholangiopancreatography. Radiology 1997;202:663-9.
16. Soto JA, Barish MA, Yucel EK, Siegenberg D, Ferrucci JT, Chuttani R. Magnetic resonance cholangiography: comparison with endoscopic retrograde cholangiopancreatography. Gastroenterology 1996;110:589-97.
17. Hintze RE, Adler A, Veltzke W, Abou-Rebyeh H, Hammerstingl R, Vogl T, et al. Clinical significance of magnetic resonance cholangiopancreatography (MRCP) compared to endoscopic retrograde cholangiopancreatography (ERCP). Endoscopy 1997;29:182-7.
18. Leyendecker JR, Elsayes KM, Gratz BI, Brown JJ. MR cholangiopancreatography: spectrum of pancreatic duct abnormalities. AJR Am J Roentgenol 2002;179:1465-71.
19. Calvo MM, Bujanda L, Calderon A, Heras I, Cabriada JL, Bernal A, et al. Comparison between magnetic resonance cholangiopancreatography and ERCP for evaluation of the pancreatic duct. Am J Gastroenterol 2002;97:347-53.
20. Sugita R, Nomiya T. Disappearance of the common bile duct signal caused by oral negative contrast agent on MR cholangiopancreatography. J Comput Assist Tomogr 2002;26:448-50.
21. Takahara T, Saeki M, Nosaka S, Shimoyamada K, Suemitsu I, Nakajima Y, et al. The use of high concentration ferric ammonium citrate (FAC) solution as a negative bowel contrast agent: application in MR cholangiography. Nippon Igaku Hoshasen Gakkai Zasshi 1995;55:697-9.
22. Small WC, DeSimone-Macchi D, Parker JR, Sukerkar A, Hahn PF, Rubin DL, et al. A multisite phase III study of the safety and efficacy of a new manganese chloride-based gastrointestinal contrast agent for MRI of the abdomen and pelvis. J Magn Reson Imaging 1999;10:15-24.